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Abstract
Background: Reduced blood or cerebrospinal fluid levels of allopregnanolone are involved in menstrual cycle-linked
CNS disorders, such as catamenial epilepsy. This condition, like menstrually-related migraine, is characterized by severe,
treatment-resistant attacks. We explored whether there were differences in allopregnanolone, progesterone and tes-
tosterone serum levels between women with menstrually-related migraine (MM, n¼ 30) or postmenopausal migraine
without aura who had suffered from menstrually-related migraine during their fertile age (PM, n¼ 30) and non-headache
control women in fertile age (FAC, n¼ 30) or post-menopause (PC, n¼ 30).
Methods: Participants were women with migraine afferent to a headache centre; controls were female patients’
acquaintances. Serum samples obtained were analyzed by HPLC-ESI-MS/MS.
Results: In menstrually-related migraine and postmenopausal migraine groups, allopregnanolone levels were lower than
in the respective control groups (fertile age and post-menopause) (p< 0.001, one-way analysis of variance followed by
Tukey-Kramer post-hoc comparison test) while progesterone and testosterone levels were similar. By grouping together
patients with migraine, allopregnanolone levels were inversely correlated with the number of years and days of migraine/
3 months (p  0.005, linear regression analysis).
Conclusion: Decreased GABAergic inhibition, due to low allopregnanolone serum levels, could contribute to
menstrually-related migraine and persistence of migraine after menopause. For the management of these disorders, a
rise in the GABAergic transmission by increasing inhibitory neurosteroids might represent a novel strategy.
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Introduction
The cyclical fluctuations of steroid hormones in women
affect susceptibility to various neurological disorders
(1). The central nervous system (CNS), in turn, can
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metabolize and synthesize steroid hormones, collective-
ly referred to as neurosteroids, which influence neuro-
nal homeostasis by modulating the balance between
neuroexcitation and neuroinhibition (2,3). The circulat-
ing steroid hormones, for their lipophilicity, penetrate
the blood-brain barrier (BBB) and serve as precursors
for the synthesis of neurosteroids. Among these,
allopregnanolone (3a,5a-tetrahydroprogesterone), a
derivative of pregnenolone and progesterone, shows
neuroprotective, sedative, anesthetic, anxiolytic and
antiepileptic properties. These effects depend mostly
on allopregnanolone’s ability to act as a positive allo-
steric modulator of the GABA(A) receptor complex
and therefore on its inhibitory effect on neuronal excit-
ability (4,5). In addition, allopregnanolone has proved
to exert analgesic effects and the capability to prevent
or reverse maladaptive changes and painful behaviours
that occur after nervous system damage in various
experimental neuropathic conditions, including
chemotherapy-evoked neuropathic pain in rats (6).
The downregulation of neurosteroid biosynthesis
has been considered to be a possible contributor to
the development of menstrual cycle-linked CNS disor-
ders (7). Actually, reduced levels of allopregnanolone
in the peripheral blood or cerebrospinal fluid were
found to be associated with premenstrual dysphoric
disorder, premenstrual syndrome, and catamenial
epilepsy (8,9). Indeed, the ratio of allopregnanolone
to progesterone decreases across the menstrual cycle,
from the follicular to the luteal phase (10). Catamenial
epilepsy is characterized by seizure exacerbation during
particular phases of women’s menstrual cycles and
refractoriness to specific treatments such as benzodia-
zepines and valproic acid (11). Nevertheless, in animal
models of this condition, progesterone reduces seizure
susceptibility, partly through its conversion to allopreg-
nanolone, which enhances GABA function and thereby
inhibits neuronal excitability (8).
Another neurological condition, linked to hormonal
fluctuations, disabling, and difficult to treat, is men-
strual migraine. This subtype of migraine is character-
ized by menstrual attacks occurring from 2 days before
to 3 days after the beginning of the menstrual flow.
Menstrual attacks are longer, more disabling, resistant
to the treatment, and tend to recur more than non-
menstrual attacks (12). Moreover, these attacks are
associated with an increased risk of chronification; in
fact, many women who suffer from chronic migraine
and analgesic overuse initially suffered from
menstrually-related migraine (13). The main trigger of
menstrual attacks is believed to be the decrease in
estrogen concentration after being exposed to high
levels for several days (14). However, the mechanisms
that mediate this effect, which appears only in some
women with migraine but not in all, are unknown.
After menopause, the prevalence of migraine falls by
about one-half, at least partly as a result of hormonal
stability (15). Nevertheless, in many women migraine
does not end after menopause. In these cases, migraine
seems associated with higher levels of mood disorders,
disabilities and menopausal symptoms (16). The mech-
anisms of persisting migraine after menopause and hor-
monal changes in this condition have also been poorly
studied (17).
We hypothesized a role of allopregnanolone, as in
catamenial epilepsy, also in menstrually-related and
postmenopausal migraine. Therefore the objectives of
our pilot study were to evaluate the serum levels of
allopregnanolone, progesterone and testosterone in
women suffering from menstrually-related migraine
and in women who had suffered from it during their
fertile age, then continued to suffer from migraine also
after menopause, and to compare them with serum
levels of these hormones in non-headache women,
both in fertile age and in post-menopause, as controls.
Another objective was to explore whether, overall, in
migraine women, there was a relationship between
serum concentrations of allopregnanolone and the
severity of migraine.
Methods
Study groups
This pilot, cross-sectional, study involved fertile and
menopausal women (Table 1). Fertile women (aged
18 to 45 years) comprised 30 women diagnosed with
menstrually-related migraine without aura (MM
group) according to the diagnostic criteria of the
International Classification of Headache Disorders,
3rd edition (ICHD-3, appendix A1.1.2) (18) and 30
non-headache age-matched women as control (FAC,
fertile age control group). Menopausal women (aged
no more than 65 years and in spontaneous menopause
for at least 1 year) comprised 30 women suffering from
migraine without aura (PM, postmenopausal migraine
group) who had suffered from menstrually-related
migraine during their fertile age according to the
diagnostic criteria of the ICHD-3 (18) and 30
non-headache, age-matched women as control (PC,
postmenopausal control group). Only subjects with
absence of major medical or psychiatric comorbidities,
normal liver and kidney functions were included in the
study; women of FAC and PC groups were required to
present no more than 3 days of tension-type headache
per month and no diagnosis of any other type of pri-
mary or secondary headache, according to ICHD-3
criteria (18). Women taking hormonal therapy
(contraceptive or post-menopause therapy), migraine
prophylaxis, drugs that could modify allopregnanolone
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levels and unable to understand the study purpose were
excluded. The women with migraine were enrolled
from consecutive patients attending, for the first time,
at the Headache Centre of the University Hospital of
Modena; non-headache women were patients’ acquain-
tances. All women provided their written consent to
participation in the study, which was conducted in
accordance with the ethical principles of the Helsinki
Declaration, last edition (2013) and approved by the
Ethics Committee of Area Vasta Emilia Nord (Italy)
(prot. 0013510/18). The subjects were enrolled from
July 2018 to May 2019.
Procedures
A sample of venous blood was collected in the morning
at fast from each woman enrolled in the study for the
quantitative determination of allopregnanolone, pro-
gesterone and testosterone. The samples (10 mL) were
allowed to clot at room temperature for 1 h and then
centrifuged at 2000 g for 10 min at þ4C to collect
sera. In fertile women (MM and FAC groups), blood
samples were taken between the 7th and 10th day of the
menstrual cycle and, in women with migraine (MM and
PM groups), during the interictal period, at least 2 days
after the last migraine attack. At the medical examina-
tion, a form was compiled for each subject to collect
personal data, life habits, clinical history and, for MM
and PM groups, also the history and characteristics of
migraine.
Sample processing and LC-MS/MS analysis
Calibrators in human albumin and serum samples from
the subjects were purified to remove proteins and phos-
pholipids, evaporated to dryness and derivatized prior
to LC-MS/MS. Chromatographic analyses were per-
formed on a Kinetex XB-C18 column under gradient
elution and the target compounds were detected by
multiple reaction monitoring (MRM) in positive ion
electrospray mode. Three selected MS/MS transitions
were monitored for each analyte and deuterated allo-
pregnanolone (internal standard) to achieve unambig-
uous identification. Serum levels of allopregnanolone,
progesterone and testosterone were determined via the
calibration curve calculated by plotting concentration
against the ratio of analyte area to that of the internal
standard. Details concerning chemicals, sample proc-
essing and LC-MS/MS quantitative analyses are pro-
vided in the Supplementary material.
Data and statistical analysis
All collected data, made anonymous, were entered into
a specific database. Descriptive analysis of all variables
was conducted. We compared the demographic and
headache characteristics in the studied groups; subse-
quently, we assessed the serum levels of allopregnano-
lone, progesterone and testosterone in each migraine
group (MM and PM) compared to those in the corre-
spondent control group (FAC and PC) and the levels in
the MM group compared to those in the PM group.
Table 1. Demographics and migraine characteristics (MM: menstrually-related migraine group; FAC: fertile age control group; PM:
postmenopausal migraine group; PC: postmenopausal control group).
Variable
Fertile age (%) Postmenopause (%)
MM
(n¼ 30)
FAC
(n¼ 30)
PM
(n¼ 30)
PC
(n¼ 30)
Mean age SD 33.5 7.1 30.9 7.9 56.6 4.5# 56.1 4.5#
Age range (years) 19 45 18 44 50 65 50 63
BMI (kg/m2) (mean SD) 23.0 3.3 23.5 4.2 24.1 4.5 23.1 2.4
Menstrual cycle lengths (mean days SD) 27.8 1.1 28.4 1.0 0 0
Range of menstrual cycle length (days) 26 30 26 31 0 0
Married (%) 21 (70) 9 (30)§ 24 (80) 26 (87)
Employed (%) 24 (80) 17 (57) 22 (73) 26 (87)
Degree (%) 5 (17) 21 (70)¥ 11 (37)$ 6 (20)
Smokers (%) 5 (17) 6 (20) 5 (17) 4 (13)
Alcohol consumption (%) 16 (53) 21 (70) 13 (43) 21 (70)
Coffee consumption (%) 21 (70) 17 (57) 16 (53) 19 (63)
Years of migraine (mean SD) 17.4 8.9* 0 33.5 11.9 0
Migraine days/3 months (mean SD) 25.5 25.3 0 35.1 24.5 0
#p< 0.001 vs. MM and FAC groups, one-way analysis of variance followed by Tukey-Kramer post-hoc comparison test.
§p¼ 0.001 vs. MM, PM and PC groups.
¥p< 0.001 vs. MM, PM and PC groups.
$p¼ 0.002, vs. MM and PC groups, chi-squared test for the homogeneity of odds.
*p< 0.001 vs. PM, one-way analysis of variance followed by the Tukey-Kramer post-hoc comparison test.
Rustichelli et al. 3
Furthermore, we investigated whether there was a rela-
tionship between serum concentrations of allopregna-
nolone and the severity of the migraine assessed as
years of migraine and number of migraine days in the
last 3 months, considering MM and PM groups indi-
vidually and also all women with migraine together
(MM and PM groups, n¼ 60).
Statistical analysis was carried out by StataIC 13
software. The continuous variables normally distribut-
ed were expressed as mean standard deviation (SD)
and the dichotomous variables as counts and percen-
tages. The comparison between means was done by
one-way analysis of variance followed by the Tukey-
Kramer post-hoc comparison test, while the chi-
squared test for the homogeneity of odds was used
for binary variables. The magnitude of the mean differ-
ences in allopregnanolone levels (effect size) was deter-
mined with Cohen’s d. Linear regression analysis was
conducted to assess the relationship between serum
level of allopregnanolone (independent variable) and
migraine seriousness (dependent variable). The magni-
tude of the dependence between the above-mentioned
variables was explored using the R2 value. Differences
were considered significant if the p-value (two-tailed)
was lower than 0.05.
Results
Analyses of allopregnanolone, progesterone and testos-
terone (Figure 1) in fertile women showed that allo-
pregnanolone levels were significantly lower in the
women with migraine of the MM group (mean val-
ue SD: 52 18 pg/mL) than in the FAC control
group (mean value SD: 78 36 pg/mL, p< 0.001),
while progesterone levels were similar between MM
group (mean value SD: 135 47 pg/mL) and FAC
group (mean value SD: 162 120 pg/mL, p¼ 0.30);
also testosterone levels showed no difference between
MM group (mean valueSD: 298 116 pg/mL) and
the FAC group (mean value SD: 327 124 pg/mL,
p¼ 0.43, one-way analysis of variance followed by
Tukey-Kramer post-hoc comparison test). Cohen’s d
value for allopregnanolone serum levels between MM
and FAC was 1.05 [1.690.4]. Analyses of serum
samples in the post-menopause groups showed allo-
pregnanolone levels significantly lower in the PM
group (mean valueSD: 25 13 pg/mL) compared
to the respective PC control group (mean valueSD:
80 17 pg/mL, p< 0.001); conversely, progesterone
levels were similar between the PM group (mean
value SD: 88 24 pg/mL) and PC group (mean
value SD: 106 83 pg/mL, p¼ 0.94) and also testos-
terone levels did not differ in the PM group (mean
value SD: 209 88 pg/mL) compared to the PC
group (mean valueSD: 201 56 pg/mL, p> 0.99,
one-way analysis of variance followed by Tukey-
Kramer post-hoc comparison test). Cohen’s d value
for allopregnanolone serum levels between PM and
PC was 3.71 [4.692.72]. Postmenopausal
women with migraine (PM) presented serum levels sig-
nificantly lower than those in fertile age (MM) for all
the target analytes: Allopregnanolone (p< 0.001), pro-
gesterone (p¼ 0.027) and testosterone (p< 0.001, one-
way analysis of variance followed by Tukey-Kramer
post-hoc comparison test). Cohen’s d value for allo-
pregnanolone serum levels between PM and MM was
1.68 [2.271.09].
Considering MM, serum levels of allopregnanolone
presented a negative correlation with years of migraine
(R2¼ 0.13, p¼ 0.069) and a statistically significant
negative correlation with migraine days in the last
3 months (R2¼ 0.18, p¼ 0.019; linear regression anal-
ysis). Serum levels of allopregnanolone in the PM
group presented a negative correlation, although not
statistically significant, with both years of migraine
(R2¼ 0.002, p¼ 0.81) and migraine days in the last 3
months (R2¼ 0.04, p¼ 0.33; linear regression analysis).
Indeed, considering both migraine groups together
(MM plus PM, n¼ 60) (Figure 2), serum levels of allo-
pregnanolone presented a statistically significant nega-
tive correlation with years of migraine (R2¼ 0.19,
p¼ 0.001) and with migraine days in the last three
months (R2¼ 0.13, p¼ 0.005; linear regression
analysis).
Discussion
Migraine and epilepsy are episodic disorders with dis-
tinct characteristics but sharing cortical hyperexcitabil-
ity, probably due to an imbalance between excitatory
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Figure 1. Serum levels (mean SD) of allopregnanolone, pro-
gesterone and testosterone in fertile age (MM and FAC groups)
and postmenopausal (PM and PC groups) women.
#p< 0.001 vs. FAC group; §p< 0.001 vs. PC and MM groups;
¥p¼ 0.027 vs. MM group; p< 0.001 vs. MM group, one-way
analysis of variance followed by the Tukey-Kramer post-hoc
comparison test.
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(glutamate) and inhibitory (GABA) factors (19,20).
Low levels of allopregnanolone have been hypothesized
underlying catamenial epilepsy, a menstrual cycle-
related seizure, refractory to treatment with specific
anticonvulsant drugs (11). Perhaps either menstrually-
related migraine or catamenial epilepsy might be
driven by dysfunctions in the same steroid regulation
mechanisms, particularly low allopregnanolone
levels. Actually, we found that women with migraine
(Figure 1, MM and PM groups) had significantly lower
allopregnanolone serum levels compared to those mea-
sured in their respective controls FAC and PC groups
(p< 0.001, one-way analysis of variance followed by
Tukey-Kramer post-hoc comparison test). Moreover,
according to Sawilowsky (21), the magnitude of the
difference of allopregnanolone levels was large between
MM and FAC and huge between PM and PC, even if
negative. However, to confirm the role of low allopreg-
nanolone levels in menstrually-related migraine, com-
parative studies are needed that take also into account
women suffering from migraine without menstrual
attacks.
Recent studies suggest that allopregnanolone has a
specific neuroprotective action in the central and
peripheral nervous system and a beneficial effect in
neurodegenerative disorders (3,22) in which an inflam-
matory activation of the microglia and astrocytes is
present. Neuroinflammation is a physiological response
to infection or injury but if it becomes chronic, it indu-
ces neurodegeneration (23). Neuroinflammation plays
an important role also in migraine, in inducing central
sensitization and chronicity of the disorder (24). Really,
in experimental models of migraine, allopregnanolone
is capable of extinguishing the neurogenic inflamma-
tion. In particular, in trigeminal pain, allopregnano-
lone blocks neurogenic inflammation, probably with
mechanisms mediated by the GABA(A) receptor (25).
In another model of migraine (neurogenic edema in the
rat meninges) allopregnanolone reduces plasma extrav-
asation induced by electrical stimulation of the trigem-
inal ganglion and substance P (26). In addition,
allopregnanolone regulates neuroinflammatory
responses also by inhibiting TLR4-dependent pro-
inflammatory signalling (27,28). In the context
of migraine, impaired neuronal homeostasis for inade-
quate levels of allopregnanolone could result in a lower
neuroprotective, analgesic and anti-inflammatory
action. It was unlikely that the reduced allopregnano-
lone levels in the studied women with migraine were the
consequence of ovarian insufficiency, since the serum
concentrations of progesterone and testosterone
showed no differences compared to control females.
The adrenal cortex contributes largely to the circulat-
ing levels of allopregnanolone, either directly or
through the synthesis of a precursor, peripherally con-
verted to allopregnanolone. This neurosteroid is also
synthesized in the nervous tissue by specific enzymes,
crosses the BBB, and its synthesis is influenced by neu-
roinflammation (29). Low concentrations of allopreg-
nanolone have been found in other conditions
characterized, like migraine, by neuroinflammation
such as Parkinson’s and Alzheimer’s disease and mul-
tiple sclerosis (3). Thus, we assumed that significantly
lower allopregnanolone levels in patients with migraine
(both MM and PM groups) than in non-headache con-
trol women were possibly associated with migraine.
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Figure 2. Correlation between allopregnanolone serum level and (a) years of migraine (p¼ 0.001) and (b) migraine days/3 months
(p¼ 0.005, linear regression analysis) in migraine groups (MM plus PM, n¼ 60).
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Indeed, non-headache women (FAC and PC groups)
showed no difference in allopregnanolone levels,
despite one group consisting of young women in fertile
age (Table 1) and the other of postmenopausal women.
Therefore, in migraine women, reduced levels of allo-
pregnanolone could contribute to the persistence of
migraine even after menopause, when instead, due to
the complete cessation of the monthly cycling of estro-
gen, migraine generally improves and its prevalence
decreases by about half (30). This was further sup-
ported by the large magnitude of effect, evaluated by
Cohen’s d (21), of the lower levels of allopregnanolone
found in the PM group compared with the MM one.
In fertile age women, the timing of blood sampling is
crucial for the interpretation of allopregnanolone
levels. In fact, the levels of this neurosteroid increase
physiologically in the late luteal phase while after men-
opause its fluctuations are limited (10,29). Recently,
allopregnanolone serum levels have been found to be
significantly increased in patients with episodic and
chronic migraine compared to healthy controls. Since
this study (31) does not specify the phase of the sam-
pling, and not even how many women were of fertile or
menopausal age and the number of males (apart from
those with cluster headache), the comparison with our
results is unfeasible.
In preclinical experimental models, allopregnano-
lone exhibits pronounced analgesic properties, but
few studies focused on the relationship between pain
and allopregnanolone in clinical populations (32). Two
studies in US Army male veterans show that allopreg-
nanolone levels are inversely related to pain (muscle
soreness, chest pain, low back pain and total pain,
including headache), suggesting that allopregnanolone
may act as a potent endogenous analgesic and that
supplementation with exogenous allopregnanolone
could have therapeutic potential (33,34). Notably,
grouping all women with migraine together (MM
plus PM) (Figure 2), we found that serum concentra-
tions of allopregnanolone were significantly and
inversely correlated with both the history of migraine
(years) (p¼ 0.001) and number of migraine days in the
last three months (p¼ 0.005, linear regression analysis),
even if the effect size of these correlations was mild to
moderate according to Cohen (35). These results sup-
ported the possibility of an anti-migraine action of allo-
pregnanolone, not only an analgesic one.
We did not find (Figure 1) differences in testosterone
and progesterone levels between MM and the corre-
sponding non-headache control group (FAC).
Postmenopausal migraine women (PM group) had sig-
nificantly lower levels of these hormones than women
in fertile age, but there were no differences compared to
postmenopausal, non-headache control women (PC
group). These results were in agreement with the obser-
vation that testosterone, in women who do not take
estrogens, does not intervene in migraine (36).
Our study has limitations. The sample was of small
size (Table 1), being a pilot study. However, it was
conducted rigorously and there are no significant dif-
ferences among groups regarding lifestyle. In women of
fertile age, analyte determinations were performed in
the follicular phase when allopregnanolone levels are
physiologically lower than in the luteal phase (29).
Therefore, the differences found between women with
migraine and the corresponding age-matched non-
headache controls were relevant. However, measuring
the levels of allopregnanolone in late luteal phase in
women with and without menstrually-related migraine
might have provided a more relevant insight on the
mechanism of menstrual attack. Blood sampling was
planned during the late follicular phase in order to
avoid menstrual attack and compare allopregnanolone
levels between women of fertile and postmenopausal
age, since in this phase the levels should be similar
and allopregnanolone levels were not found to vary
with age in women (29).
Conclusion
Women suffering from migraine presented low serum
levels of allopregnanolone, a neurosteroid that modu-
lates GABAergic inhibition (9). In this context, the
increased cortical excitability found in migraine may
not be sufficiently offset by the allopregnanolone-
mediated enhancement of the GABAergic transmis-
sion. Consequently, the reduced GABAergic inhibition
could inadequately protect women with migraine
against inflammatory and algogenic stimuli. In partic-
ular, it could contribute to menstrually-related
migraine and persistence of migraine even after meno-
pause. Moreover, serum levels of allopregnanolone, in
our study carried out in the clinic, were inversely relat-
ed to the years and frequency of migraine, also indicat-
ing an anti-migraine and not only analgesic action of
this neurosteroid.
Our findings, obtained in a pilot study, if confirmed
in larger case series, could provide the background for
novel therapies aimed at raising the GABAergic trans-
mission by drugs increasing the biosynthetic pathway
of inhibitory neurosteroids or by the use of synthetic
allopregnanolone analogues for the treatment of both
menstrually-related and postmenopausal migraine.
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Clinical implications
• Women suffering from migraine, either menstrually-related or postmenopausal, had lower allopregnano-
lone serum levels than non-headache control women.
• In these women with migraine, allopregnanolone serum levels were inversely related to the years and
frequency of migraine.
• Drugs increasing the biosynthetic pathway of inhibitory neurosteroids or synthetic allopregnanolone
analogues could represent a possible strategy for the management of menstrually-related and postmeno-
pausal migraine.
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